-
Kidney Int 2022
-
GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes
+
NDT 2023
+
Removing race from the CKD-EPI equation and its impact on prognosis in a predominantly White European population